These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 28028737)

  • 1. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.
    Breul J; Lundström E; Purcea D; Venetz WP; Cabri P; Dutailly P; Goldfischer ER
    Adv Ther; 2017 Feb; 34(2):513-523. PubMed ID: 28028737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
    Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
    BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer.
    Heyns CF; Simonin MP; Grosgurin P; Schall R; Porchet HC;
    BJU Int; 2003 Aug; 92(3):226-31. PubMed ID: 12887472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L; Schalken JA; Cabri P; Maisonobe P; de la Taille A;
    BJU Int; 2014 Oct; 114(4):608-16. PubMed ID: 24806330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer.
    Merseburger AS; Hupe MC
    Adv Ther; 2016 Jul; 33(7):1072-93. PubMed ID: 27246172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptorelin in the management of prostate cancer.
    Ploussard G; Mongiat-Artus P
    Future Oncol; 2013 Jan; 9(1):93-102. PubMed ID: 23252566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial with new triptorelin sustained release formulations in prostatic carcinoma.
    Minkov NK; Zozikov BI; Yaneva Z; Uldry PA
    Int Urol Nephrol; 2001; 33(2):379-83. PubMed ID: 12092661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptorelin 6-month formulation in the management of patients with locally advanced and metastatic prostate cancer: an open-label, non-comparative, multicentre, phase III study.
    Lundström EA; Rencken RK; van Wyk JH; Coetzee LJ; Bahlmann JC; Reif S; Strasheim EA; Bigalke MC; Pontin AR; Goedhals L; Steyn DG; Heyns CF; Aldera LA; Mackenzie TM; Purcea D; Grosgurin PY; Porchet HC
    Clin Drug Investig; 2009; 29(12):757-65. PubMed ID: 19888782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer.
    Teillac P; Heyns CF; Kaisary AV; Bouchot O; Blumberg J
    Horm Res; 2004; 62(5):252-8. PubMed ID: 15499224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.
    Østergren PB; Kistorp C; Fode M; Henderson J; Bennedbæk FN; Faber J; Sønksen J
    J Urol; 2017 Jun; 197(6):1441-1447. PubMed ID: 27939836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic model of the testosterone effects of triptorelin administered in sustained release formulations in patients with prostate cancer.
    Romero E; Vélez de Mendizabal N; Cendrós JM; Peraire C; Bascompta E; Obach R; Trocóniz IF
    J Pharmacol Exp Ther; 2012 Sep; 342(3):788-98. PubMed ID: 22691297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
    Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
    Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.
    Crawford ED; Twardowski PW; Concepcion RS; Hafron JM; Harris RG; Moul JW; Gordan LN; Petrylak DP; Atkinson SN; Boldt-Houle DM; Keane TE; Higano CS; Henderson RJ; Kader AK; Hussain MH; Shore ND
    J Urol; 2020 Apr; 203(4):743-750. PubMed ID: 31580749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
    Wilke D; Patil N; Hollenhorst H; Bowes D; Rutledge R; Ago C
    Pharmacotherapy; 2018 Mar; 38(3):327-333. PubMed ID: 29337395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.